Replenishment and enrichment of ocular surface lubrication
An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.
1. A method of treating contact lenses comprising contacting one or more contact lenses with an effective amount of a composition comprising an isolated, purified, or recombinant PRG4 in an ophthalmically acceptable and balanced salt solution, wherein the treating comprises cleaning, chemical disinfecting, storing, rinsing contact lenses or a combination thereof.
2. The method of claim 1 , wherein the composition further comprises a contact lens care agent comprising a surfactant, a protease, a disinfectant, or a combination thereof.
3. The method of claim 2 , wherein the composition comprises a surfactant.
4. The method of claim 2 , wherein the composition comprises a protease.
5. The method of claim 2 , wherein the composition comprises a disinfectant.
6. The method of claim 1 , wherein the composition further comprises a viscosity increasing component.
7. The method of claim 1 , wherein the composition further comprises a chelating component.
8. The method of claim 1 , wherein the composition comprises the PRG4 in a concentration of 10-10,000 μg/mL.
9. The method of claim 1 , wherein the composition further comprises an effective concentration of sodium hyaluronate or hyaluronic acid.
10. The method of claim 9 , wherein the concentration of sodium hyaluronate or hyaluronic acid is 10 to 100,000 μg/mL.
11. The method of claim 9 , wherein the concentration of sodium hyaluronate or hyaluronic acid is 500 to 5,000 μg/mL.
12. The method of claim 1 , comprising a therapeutically effective concentration of surface active phospholipid selected from the group consisting of L-α-dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin.
13. The method of claim 12 , wherein the therapeutically effective concentration of the surface active phospholipid is 10 to 10,000 μg/mL.
14. The method of claim 1 , wherein the ophthalmically acceptable and balanced salt solution comprises at least three different electrolytes selected from the group consisting of sodium phosphate, sodium chloride, potassium chloride, sodium bicarbonate, potassium bicarbonate, calcium chloride, magnesium chloride, sodium acetate, sodium citrate, hydrochloric acid, and sodium hydroxide.
15. The method of claim 1 , wherein the PRG4 has an average molar mass of between 50 kDa and 400 kDa.
16. The method of claim 15 , wherein the PRG4 comprises a lubricating fragment, multimer, or a homolog thereof.
17. The method of claim 15 , wherein the PRG4 is a recombinant PRG4 protein or a functional fragment thereof.
18. The method of claim 15 , wherein the PRG4 is an isolated or purified PRG4 protein.